Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series
OBJECTIVES: To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS). DESIGN: Single-center, retrospective case series. SETTING: PICU and cardiac ICU (CICU) at a large, quaternary children...
Uložené v:
| Vydané v: | Critical care explorations Ročník 5; číslo 9; s. e0978 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Hagerstown, MD
Lippincott Williams & Wilkins
12.09.2023
Wolters Kluwer |
| Predmet: | |
| ISSN: | 2639-8028, 2639-8028 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | OBJECTIVES:
To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS).
DESIGN:
Single-center, retrospective case series.
SETTING:
PICU and cardiac ICU (CICU) at a large, quaternary children's hospital in the United States.
PATIENTS:
Twenty-three pediatric patients with CRVS who were prescribed synthetic angiotensin II at the discretion of bedside clinicians from January 2018 to April 2023.
INTERVENTIONS:
None.
MEASUREMENTS AND MAIN RESULTS:
Twenty-three patients (20 in PICU, 3 in CICU) with a median age of 10.4 years (interquartile range [IQR] 1.5-18.5) received angiotensin II over the study period, 70% of whom died. At the time of angiotensin II initiation, 17 patients (74%) were receiving one or more forms of extracorporeal therapy, and median Pediatric Logistic Organ Dysfunction-2 Score-2 in the prior 24 hours was 9 (IQR 7-11). The median time between initiation of the first vasoactive agent and angiotensin II was 127 hours (IQR 13-289), and the median total norepinephrine equivalent (NED) at initiation was 0.65 μg/kg/min (IQR 0.36-0.78). The median duration of therapy was 27 hours (IQR 4-68), and at each timepoint assessed, patients had median improvement in NED and mean arterial pressure (MAP) with treatment. Survivors initiated angiotensin II nearly 3 days earlier in vasoactive course (91.5 hr vs 161 hr, p = 0.23), and had both greater reduction in NED (-75% [IQR -96 to -50] vs +2.1% [IQR -55 to 33], p = 0.008) and greater increase in MAP (+15 mm Hg [IQR 10-27] vs -1.5 mm Hg [IQR -27 to 18], p = 0.052) at angiotensin II discontinuation.
CONCLUSIONS:
We demonstrate reduction in NED and improved MAP following initiation of angiotensin II in critically ill children with CRVS. Further prospective work is needed to examine optimal timing of angiotensin II initiation, appropriate patient selection, and safety in this population. |
|---|---|
| AbstractList | OBJECTIVES:. To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS). DESIGN:. Single-center, retrospective case series. SETTING:. PICU and cardiac ICU (CICU) at a large, quaternary children’s hospital in the United States. PATIENTS:. Twenty-three pediatric patients with CRVS who were prescribed synthetic angiotensin II at the discretion of bedside clinicians from January 2018 to April 2023. INTERVENTIONS:. None. MEASUREMENTS AND MAIN RESULTS:. Twenty-three patients (20 in PICU, 3 in CICU) with a median age of 10.4 years (interquartile range [IQR] 1.5–18.5) received angiotensin II over the study period, 70% of whom died. At the time of angiotensin II initiation, 17 patients (74%) were receiving one or more forms of extracorporeal therapy, and median Pediatric Logistic Organ Dysfunction-2 Score-2 in the prior 24 hours was 9 (IQR 7–11). The median time between initiation of the first vasoactive agent and angiotensin II was 127 hours (IQR 13–289), and the median total norepinephrine equivalent (NED) at initiation was 0.65 μg/kg/min (IQR 0.36–0.78). The median duration of therapy was 27 hours (IQR 4–68), and at each timepoint assessed, patients had median improvement in NED and mean arterial pressure (MAP) with treatment. Survivors initiated angiotensin II nearly 3 days earlier in vasoactive course (91.5 hr vs 161 hr, p = 0.23), and had both greater reduction in NED (–75% [IQR –96 to –50] vs +2.1% [IQR –55 to 33], p = 0.008) and greater increase in MAP (+15 mm Hg [IQR 10–27] vs –1.5 mm Hg [IQR –27 to 18], p = 0.052) at angiotensin II discontinuation. CONCLUSIONS:. We demonstrate reduction in NED and improved MAP following initiation of angiotensin II in critically ill children with CRVS. Further prospective work is needed to examine optimal timing of angiotensin II initiation, appropriate patient selection, and safety in this population. To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS).OBJECTIVESTo describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS).Single-center, retrospective case series.DESIGNSingle-center, retrospective case series.PICU and cardiac ICU (CICU) at a large, quaternary children's hospital in the United States.SETTINGPICU and cardiac ICU (CICU) at a large, quaternary children's hospital in the United States.Twenty-three pediatric patients with CRVS who were prescribed synthetic angiotensin II at the discretion of bedside clinicians from January 2018 to April 2023.PATIENTSTwenty-three pediatric patients with CRVS who were prescribed synthetic angiotensin II at the discretion of bedside clinicians from January 2018 to April 2023.None.INTERVENTIONSNone.Twenty-three patients (20 in PICU, 3 in CICU) with a median age of 10.4 years (interquartile range [IQR] 1.5-18.5) received angiotensin II over the study period, 70% of whom died. At the time of angiotensin II initiation, 17 patients (74%) were receiving one or more forms of extracorporeal therapy, and median Pediatric Logistic Organ Dysfunction-2 Score-2 in the prior 24 hours was 9 (IQR 7-11). The median time between initiation of the first vasoactive agent and angiotensin II was 127 hours (IQR 13-289), and the median total norepinephrine equivalent (NED) at initiation was 0.65 μg/kg/min (IQR 0.36-0.78). The median duration of therapy was 27 hours (IQR 4-68), and at each timepoint assessed, patients had median improvement in NED and mean arterial pressure (MAP) with treatment. Survivors initiated angiotensin II nearly 3 days earlier in vasoactive course (91.5 hr vs 161 hr, p = 0.23), and had both greater reduction in NED (-75% [IQR -96 to -50] vs +2.1% [IQR -55 to 33], p = 0.008) and greater increase in MAP (+15 mm Hg [IQR 10-27] vs -1.5 mm Hg [IQR -27 to 18], p = 0.052) at angiotensin II discontinuation.MEASUREMENTS AND MAIN RESULTSTwenty-three patients (20 in PICU, 3 in CICU) with a median age of 10.4 years (interquartile range [IQR] 1.5-18.5) received angiotensin II over the study period, 70% of whom died. At the time of angiotensin II initiation, 17 patients (74%) were receiving one or more forms of extracorporeal therapy, and median Pediatric Logistic Organ Dysfunction-2 Score-2 in the prior 24 hours was 9 (IQR 7-11). The median time between initiation of the first vasoactive agent and angiotensin II was 127 hours (IQR 13-289), and the median total norepinephrine equivalent (NED) at initiation was 0.65 μg/kg/min (IQR 0.36-0.78). The median duration of therapy was 27 hours (IQR 4-68), and at each timepoint assessed, patients had median improvement in NED and mean arterial pressure (MAP) with treatment. Survivors initiated angiotensin II nearly 3 days earlier in vasoactive course (91.5 hr vs 161 hr, p = 0.23), and had both greater reduction in NED (-75% [IQR -96 to -50] vs +2.1% [IQR -55 to 33], p = 0.008) and greater increase in MAP (+15 mm Hg [IQR 10-27] vs -1.5 mm Hg [IQR -27 to 18], p = 0.052) at angiotensin II discontinuation.We demonstrate reduction in NED and improved MAP following initiation of angiotensin II in critically ill children with CRVS. Further prospective work is needed to examine optimal timing of angiotensin II initiation, appropriate patient selection, and safety in this population.CONCLUSIONSWe demonstrate reduction in NED and improved MAP following initiation of angiotensin II in critically ill children with CRVS. Further prospective work is needed to examine optimal timing of angiotensin II initiation, appropriate patient selection, and safety in this population. OBJECTIVES: To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS). DESIGN: Single-center, retrospective case series. SETTING: PICU and cardiac ICU (CICU) at a large, quaternary children's hospital in the United States. PATIENTS: Twenty-three pediatric patients with CRVS who were prescribed synthetic angiotensin II at the discretion of bedside clinicians from January 2018 to April 2023. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Twenty-three patients (20 in PICU, 3 in CICU) with a median age of 10.4 years (interquartile range [IQR] 1.5-18.5) received angiotensin II over the study period, 70% of whom died. At the time of angiotensin II initiation, 17 patients (74%) were receiving one or more forms of extracorporeal therapy, and median Pediatric Logistic Organ Dysfunction-2 Score-2 in the prior 24 hours was 9 (IQR 7-11). The median time between initiation of the first vasoactive agent and angiotensin II was 127 hours (IQR 13-289), and the median total norepinephrine equivalent (NED) at initiation was 0.65 μg/kg/min (IQR 0.36-0.78). The median duration of therapy was 27 hours (IQR 4-68), and at each timepoint assessed, patients had median improvement in NED and mean arterial pressure (MAP) with treatment. Survivors initiated angiotensin II nearly 3 days earlier in vasoactive course (91.5 hr vs 161 hr, p = 0.23), and had both greater reduction in NED (-75% [IQR -96 to -50] vs +2.1% [IQR -55 to 33], p = 0.008) and greater increase in MAP (+15 mm Hg [IQR 10-27] vs -1.5 mm Hg [IQR -27 to 18], p = 0.052) at angiotensin II discontinuation. CONCLUSIONS: We demonstrate reduction in NED and improved MAP following initiation of angiotensin II in critically ill children with CRVS. Further prospective work is needed to examine optimal timing of angiotensin II initiation, appropriate patient selection, and safety in this population. |
| Author | Goldstein, Stuart L. Stanski, Natalja L. Hutson, Tamara K. Tezel, Oguzhan Gist, Katja M. Chima, Ranjit S. |
| Author_xml | – sequence: 1 givenname: Oguzhan surname: Tezel fullname: Tezel, Oguzhan organization: Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey – sequence: 2 givenname: Tamara K. surname: Hutson fullname: Hutson, Tamara K. organization: Division of Pharmacy, Cincinnati Children's Medical Center, Cincinnati, OH – sequence: 3 givenname: Katja M. surname: Gist fullname: Gist, Katja M. organization: Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH – sequence: 4 givenname: Ranjit S. surname: Chima fullname: Chima, Ranjit S. organization: Division of Critical Care Medicine, Cincinnati Children's Medical Center, Cincinnati, OH – sequence: 5 givenname: Stuart L. surname: Goldstein fullname: Goldstein, Stuart L. organization: Division of Nephrology and Hypertension, Cincinnati Children's Medical Center, Cincinnati, OH – sequence: 6 givenname: Natalja L. surname: Stanski fullname: Stanski, Natalja L. organization: Division of Critical Care Medicine, Cincinnati Children's Medical Center, Cincinnati, OH |
| BookMark | eNqFkk9PHCEYxieNTWqt36AHjr2MhfkDjJdmM7F1EpMmbu2VsMzLDsrCFhjN9uP4SaWuadRDywUC7_N7eeB5Xxw476AoPhJ8QnDHPvf92Ql-PjrG3xSHFa27kuOKHzxbvyuOY7zONRVpScuaw-L-KhlrfstkvENeo-XOpQmSUeh83kiHFm5tfAIXjUPDgLQPqJcJ1OSt3BgH5SVEE5N0Cf2U0Y_GyuTDDi0nr25QFvXBZJq0docGa1E_GTsGcKdogZbGrS2UPbgEAV1CCj5uQSVzC7lJBLSEYCB-KN5qaSMcP81HxdXXsx_9eXnx_dvQLy5K1WLCy2rVVlwRUukaSC0p7xijQIGPmnRU4a5rCcF4RTkjNeWEQqWbFkumsea1buqjYthzRy-vxTaYjQw74aURjxs-rIUM2YsFQaq2VY2uRt7oRtKx41qrtqk1cKIYWWXWlz1rO682MKpsMUj7AvryxJlJrP2tILjpOsxJJnx6IgT_a4aYxMZEBdZKB36OouK0ZTxbZrm02Zeq_IAxgP7bh2DxJyMiZ0S8zkiWnb6SKZMeg5BvZOz_xHwvvvM2_168sfMdBDGBtGn6t_QBX1PV1g |
| CitedBy_id | crossref_primary_10_1016_j_intimp_2025_115192 crossref_primary_10_1053_j_jvca_2024_12_022 crossref_primary_10_1177_08850666241268655 |
| Cites_doi | 10.1056/NEJMoa1704154 10.1186/s13054-020-2733-x 10.1007/s00134-019-05878-6 10.1016/j.jcrc.2020.11.002 10.1007/s00467-023-05930-0 10.1097/PCC.0000000000000225 10.1097/CCM.0000000000004123 10.1097/PCC.0b013e3182917fad 10.1097/CCM.0000000000003092 10.1177/0885066620972943 10.1097/CCE.0000000000000036 10.1164/rccm.201911-2172OC 10.1164/rccm.201412-2323OC 10.1097/CCM.0000000000004511 10.1164/rccm.200207-682OC 10.1186/s13054-023-04518-2 10.1186/s13054-023-04446-1 10.1097/CCM.0000000000005317 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. 2023 |
| Copyright_xml | – notice: Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. – notice: Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. 2023 |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1097/CCE.0000000000000978 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2639-8028 |
| ExternalDocumentID | oai_doaj_org_article_1255c4f2d84f4a6d98ffc543fe81c71b PMC10499081 10_1097_CCE_0000000000000978 |
| Genre | in-brief |
| GrantInformation_xml | – fundername: National Center for Advancing Translational Sciences grantid: KL2TR001426 funderid: http://dx.doi.org/10.13039/100006108 – fundername: ; grantid: KL2TR001426 |
| GroupedDBID | 0R~ 53G AAAAV AAHPQ AAIQE AASCR ABASU ABDIG ABVCZ ABZZY ACILI ACXJB ADGGA ADHPY ADPDF AFBFQ AFDTB AHQNM AINUH AJCLO AJNWD AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMKUR AMNEI AOHHW AOQMC DIWNM EBS EEVPB FCALG GNXGY GQDEL GROUPED_DOAJ HLJTE IKREB M~E OK1 OPUJH OVD OVDNE RLZ RPM TEORI TSPGW AAYXX ACBKD ADKSD CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c5018-2b528c112f3e13a689776e6e8df196c09951100b687136816e2f450a7f0f83f43 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001275959700013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2639-8028 |
| IngestDate | Tue Oct 14 14:31:58 EDT 2025 Tue Nov 04 02:06:16 EST 2025 Mon Sep 08 05:59:53 EDT 2025 Sat Nov 29 05:58:46 EST 2025 Tue Nov 18 21:28:59 EST 2025 Wed Apr 16 02:18:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | angiotensin II sepsis pediatrics shock |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5018-2b528c112f3e13a689776e6e8df196c09951100b687136816e2f450a7f0f83f43 |
| Notes | This study was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (KL2TR001426; PI: Natalja L. Stanski). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Gist received funding from the Gerber Foundation and is a consultant for Bioporto Diagnostics and Potrero Medical. None of these entities had any say or contributed to the content of the article. The remainder of the authors report no financial disclosures or conflicts of interest relevant to this work. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://journals.lww.com/ccejournal). For information regarding this article, E-mail: natalja.stanski@cchmc.org ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/1255c4f2d84f4a6d98ffc543fe81c71b |
| PQID | 2865785287 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1255c4f2d84f4a6d98ffc543fe81c71b pubmedcentral_primary_oai_pubmedcentral_nih_gov_10499081 proquest_miscellaneous_2865785287 crossref_primary_10_1097_CCE_0000000000000978 crossref_citationtrail_10_1097_CCE_0000000000000978 wolterskluwer_health_10_1097_CCE_0000000000000978 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-September-12 |
| PublicationDateYYYYMMDD | 2023-09-12 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-September-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | Hagerstown, MD |
| PublicationPlace_xml | – name: Hagerstown, MD |
| PublicationTitle | Critical care explorations |
| PublicationYear | 2023 |
| Publisher | Lippincott Williams & Wilkins Wolters Kluwer |
| Publisher_xml | – name: Lippincott Williams & Wilkins – name: Wolters Kluwer |
| References | Watson, Carcillo, Linde-Zwirble (R1) 2003; 167 Bellomo, Wunderink, Szerlip (R13) 2020; 24 Balamuth, Weiss, Neuman (R4) 2014; 15 Smith, Newsome, Guo (R17) 2022; 37 Khanna, English, Wang (R10) 2017; 377 Bellomo, Forni, Busse (R11) 2020; 202 Weiss, Peters, Alhazzani (R6) 2020; 46 Pode-Shakked, Ceschia, Rose (R14) 2023; 27 Zimmerman, Banks, Berg (R5) 2020; 48 Goradia, Sardaneh, Narayan (R16) 2021; 61 Hartman, Linde-Zwirble, Angus (R3) 2013; 14 Weiss, Fitzgerald, Pappachan (R2) 2015; 191 Bailey, Chima, Tidmarsh (R15) 2019; 1 Sacha, Lam, Wang (R8) 2022; 50 Wieruszewski, Bellomo, Busse (R9) 2023; 27 Stanski, Pode Shakked, Zhang (R18) 2023; 38 Tumlin, Murugan, Deane (R12) 2018; 46 Okazaki, Iguchi, Evans (R7) 2020; 48 Balamuth (R4-20240807) 2014; 15 Wieruszewski (R9-20240807) 2023; 27 Watson (R1-20240807) 2003; 167 Pode-Shakked (R14-20240807) 2023; 27 Tumlin (R12-20240807) 2018; 46 Goradia (R16-20240807) 2021; 61 Bellomo (R11-20240807) 2020; 202 Weiss (R2-20240807) 2015; 191 Smith (R17-20240807) 2022; 37 Weiss (R6-20240807) 2020; 46 Hartman (R3-20240807) 2013; 14 Zimmerman (R5-20240807) 2020; 48 Khanna (R10-20240807) 2017; 377 Bailey (R15-20240807) 2019; 1 Sacha (R8-20240807) 2022; 50 Bellomo (R13-20240807) 2020; 24 Stanski (R18-20240807) 2023; 38 Okazaki (R7-20240807) 2020; 48 |
| References_xml | – volume: 27 start-page: 175 year: 2023 ident: R9 article-title: Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: An exploratory post-hoc analysis of the ATHOS-3 clinical trial. publication-title: Crit Care – volume: 37 start-page: 75 year: 2022 end-page: 82 ident: R17 article-title: A multicenter observational cohort study of angiotensin II in shock. publication-title: J Intensive Care Med – volume: 46 start-page: 949 year: 2018 end-page: 957 ident: R12 article-title: Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. publication-title: Crit Care Med – volume: 1 start-page: e0036 year: 2019 ident: R15 article-title: Synthetic human angiotensin II in pediatric patients with vasodilatory shock: A report on two patients. publication-title: Crit Care Explor – volume: 191 start-page: 1147 year: 2015 end-page: 1157 ident: R2 article-title: Global epidemiology of pediatric severe sepsis: The sepsis prevalence, outcomes, and therapies study. publication-title: Am J Respir Crit Care Med – volume: 27 start-page: 230 year: 2023 ident: R14 article-title: Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock. publication-title: Crit Care – volume: 377 start-page: 419 year: 2017 end-page: 430 ident: R10 article-title: Angiotensin II for the treatment of vasodilatory shock. publication-title: N Engl J Med – volume: 46 start-page: 10 year: 2020 end-page: 67 ident: R6 article-title: Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. publication-title: Intensive Care Med – volume: 48 start-page: e951 year: 2020 end-page: e958 ident: R7 article-title: Beneficial effects of vasopressin compared with norepinephrine on renal perfusion, oxygenation, and function in experimental septic acute kidney injury. publication-title: Crit Care Med – volume: 61 start-page: 233 year: 2021 end-page: 240 ident: R16 article-title: Vasopressor dose equivalence: A scoping review and suggested formula. publication-title: J Crit Care – volume: 38 start-page: 3099 year: 2023 end-page: 3108 ident: R18 article-title: Serum renin and prorenin concentrations predict severe persistent acute kidney injury and mortality in pediatric septic shock. publication-title: Pediatr Nephrol – volume: 48 start-page: 329 year: 2020 end-page: 337 ident: R5 article-title: Trajectory of mortality and health-related quality of life morbidity following community-acquired pediatric septic shock. publication-title: Crit Care Med – volume: 50 start-page: 614 year: 2022 end-page: 623 ident: R8 article-title: Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. publication-title: Crit Care Med – volume: 202 start-page: 1253 year: 2020 end-page: 1261 ident: R11 article-title: Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. publication-title: Am J Respir Crit Care Med – volume: 167 start-page: 695 year: 2003 end-page: 701 ident: R1 article-title: The epidemiology of severe sepsis in children in the United States. publication-title: Am J Respir Crit Care Med – volume: 24 start-page: 43 year: 2020 ident: R13 article-title: Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. publication-title: Crit Care – volume: 14 start-page: 686 year: 2013 end-page: 693 ident: R3 article-title: Trends in the epidemiology of pediatric severe sepsis*. publication-title: Pediatr Crit Care Med – volume: 15 start-page: 798 year: 2014 end-page: 805 ident: R4 article-title: Pediatric severe sepsis in US children's hospitals. publication-title: Pediatr Crit Care Med – volume: 377 start-page: 419 year: 2017 ident: R10-20240807 article-title: Angiotensin II for the treatment of vasodilatory shock. publication-title: N Engl J Med doi: 10.1056/NEJMoa1704154 – volume: 24 start-page: 43 year: 2020 ident: R13-20240807 article-title: Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. publication-title: Crit Care doi: 10.1186/s13054-020-2733-x – volume: 46 start-page: 10 year: 2020 ident: R6-20240807 article-title: Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. publication-title: Intensive Care Med doi: 10.1007/s00134-019-05878-6 – volume: 61 start-page: 233 year: 2021 ident: R16-20240807 article-title: Vasopressor dose equivalence: A scoping review and suggested formula. publication-title: J Crit Care doi: 10.1016/j.jcrc.2020.11.002 – volume: 38 start-page: 3099 year: 2023 ident: R18-20240807 article-title: Serum renin and prorenin concentrations predict severe persistent acute kidney injury and mortality in pediatric septic shock. publication-title: Pediatr Nephrol doi: 10.1007/s00467-023-05930-0 – volume: 15 start-page: 798 year: 2014 ident: R4-20240807 article-title: Pediatric severe sepsis in US children’s hospitals. publication-title: Pediatr Crit Care Med doi: 10.1097/PCC.0000000000000225 – volume: 48 start-page: 329 year: 2020 ident: R5-20240807 article-title: Trajectory of mortality and health-related quality of life morbidity following community-acquired pediatric septic shock. publication-title: Crit Care Med doi: 10.1097/CCM.0000000000004123 – volume: 14 start-page: 686 year: 2013 ident: R3-20240807 article-title: Trends in the epidemiology of pediatric severe sepsis*. publication-title: Pediatr Crit Care Med doi: 10.1097/PCC.0b013e3182917fad – volume: 46 start-page: 949 year: 2018 ident: R12-20240807 article-title: Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. publication-title: Crit Care Med doi: 10.1097/CCM.0000000000003092 – volume: 37 start-page: 75 year: 2022 ident: R17-20240807 article-title: A multicenter observational cohort study of angiotensin II in shock. publication-title: J Intensive Care Med doi: 10.1177/0885066620972943 – volume: 1 start-page: e0036 year: 2019 ident: R15-20240807 article-title: Synthetic human angiotensin II in pediatric patients with vasodilatory shock: A report on two patients. publication-title: Crit Care Explor doi: 10.1097/CCE.0000000000000036 – volume: 202 start-page: 1253 year: 2020 ident: R11-20240807 article-title: Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201911-2172OC – volume: 191 start-page: 1147 year: 2015 ident: R2-20240807 article-title: Global epidemiology of pediatric severe sepsis: The sepsis prevalence, outcomes, and therapies study. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201412-2323OC – volume: 48 start-page: e951 year: 2020 ident: R7-20240807 article-title: Beneficial effects of vasopressin compared with norepinephrine on renal perfusion, oxygenation, and function in experimental septic acute kidney injury. publication-title: Crit Care Med doi: 10.1097/CCM.0000000000004511 – volume: 167 start-page: 695 year: 2003 ident: R1-20240807 article-title: The epidemiology of severe sepsis in children in the United States. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200207-682OC – volume: 27 start-page: 230 year: 2023 ident: R14-20240807 article-title: Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock. publication-title: Crit Care doi: 10.1186/s13054-023-04518-2 – volume: 27 start-page: 175 year: 2023 ident: R9-20240807 article-title: Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: An exploratory post-hoc analysis of the ATHOS-3 clinical trial. publication-title: Crit Care doi: 10.1186/s13054-023-04446-1 – volume: 50 start-page: 614 year: 2022 ident: R8-20240807 article-title: Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. publication-title: Crit Care Med doi: 10.1097/CCM.0000000000005317 |
| SSID | ssj0002151574 |
| Score | 2.2659366 |
| Snippet | OBJECTIVES:
To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant... To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory... OBJECTIVES:. To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant... |
| SourceID | doaj pubmedcentral proquest crossref wolterskluwer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | e0978 |
| SubjectTerms | Brief Report |
| Title | Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1097/CCE.0000000000000978 https://www.proquest.com/docview/2865785287 https://pubmed.ncbi.nlm.nih.gov/PMC10499081 https://doaj.org/article/1255c4f2d84f4a6d98ffc543fe81c71b |
| Volume | 5 |
| WOSCitedRecordID | wos001275959700013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2639-8028 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002151574 issn: 2639-8028 databaseCode: DOA dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2639-8028 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002151574 issn: 2639-8028 databaseCode: M~E dateStart: 20190101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWg4oCEEAgQ4aMyElerG8dJHG5LtBUrQYW6tNpb5HXGdEVI0CYF9cKP4Zcy4yTVpgd6IYccEluO47HnjT3zhrG32gLxdEvhVFkKBQrXwQiUMKTfNomxxkd4n39MT070ep193kv1RT5hPT1w_-OOUAHHVjlZauWUScpMO2djFTnQoU3DDa2-iHr2jClag0mRxakaY-Wy9CjPFz1X4Xj5zGp7ushT9k9w5k0vyQe_GjrBbr95B_Y9NXT8iD0c8COf99_9mN2B-gn7c9ZtqyGgkjeOr65qxHVYgvs9ej6vv24b76pe8-WSI07luSH2VrRrvyPMFKfQEo6sO35u2qbcVv7sna8ucLXkWGlMiFBd8WVV8XyIAH_H53yFuq8CQbvEsOOn0O2aMXoTG2mB0_4btE_Z2fHiS_5BDMkXhCWOPyE3sdQW0ZiLIIxMohEoJpCALh1OWovAMia2uU2CFleU6DAB6VQ8M6mbOR05FT1jB3VTw3PGlXWpjhVaklYqIzOTZmiXaqeVNCCzWcCicRgKOzCTU4KMqhhPyHHwipuDFzBxXetHz8xxS_n3NMLXZYlX2z9AaSsGaStuk7aAvRnlo8B5SIcrpobmsi0owhd7iQZowPREcCYtTt_U2wvP6B2S4YngLGDhRMaKPhj2n_168T_69ZLdl4jehM-N8YoddLtLeM3u2Z_dtt0dsrvpWh_6GYb3T78XfwFq1Sjn |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Utilization+of+Synthetic+Human+Angiotensin+II+for+Catecholamine-Resistant+Vasodilatory+Shock+in+Critically+Ill+Children%3A+A+Single-Center+Retrospective+Case+Series&rft.jtitle=Critical+care+explorations&rft.au=Tezel%2C+Oguzhan&rft.au=Hutson%2C+Tamara+K.&rft.au=Gist%2C+Katja+M.&rft.au=Chima%2C+Ranjit+S.&rft.date=2023-09-12&rft.pub=Lippincott+Williams+%26+Wilkins&rft.eissn=2639-8028&rft.volume=5&rft.issue=9&rft_id=info:doi/10.1097%2FCCE.0000000000000978&rft.externalDocID=PMC10499081 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2639-8028&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2639-8028&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2639-8028&client=summon |